Treatment of NSCLC: Best Practices from the University of Kansas Cancer Center and Satellites : Episode 9
Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations
Vinay Raja, MD, explores the management of patients with Stage-III disease and actionable EGFR/ALK aberrations, as well as the treatment approach for patients with PD-L1 <1%.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F555f5be80532573a6654f0b562c43e11aedf99df-1200x857.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.")
